Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos NV announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of EUR 100 million revenues, a growth of 30% compared to 2008. Galapagos' service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009.

13 Nov 2009

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

The U.S. Food and Drug Administration has approved the use of the CSL Limited's 2009 H1N1 influenza vaccine to include children ages 6 months and older. This vaccine was previously approved only for use in adults, ages 18 years and older.

13 Nov 2009

PDL BioPharma to pay $200 million special dividend payment to stockholders

PDL BioPharma, Inc. (PDL) today announced that it will pay a $200 million special dividend to stockholders, with part of the proceeds from the $300 million securitization transaction completed on November 2, 2009.

13 Nov 2009

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Innomed/BioRobotics to be Health Robotics' exclusive strategic partner in Korea

Health Robotics today announced that Innomed/BioRobotics, on the heels of its prior market success with Oncology Surgery robots, has exclusively selected Health Robotics' CytoCare(TM) Robot to reach its objective to become the gold standard for Oncology Robotics IV Admixtures in the Republic of Korea and synergistically provide an end-to-end Cancer Robotics solution.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.

12 Nov 2009

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals, Inc. announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

12 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

NMO patients are misdiagnosed with Multiple Sclerosis, says Mayo Clinic neurologist

Thousands of Neuromyelitis Optica (NMO) patients are potentially being misdiagnosed with Multiple Sclerosis (MS), according to Mayo Clinic Neurologist Sean Pittock, M.D., largely due to lack of awareness of NMO within the medical community.

12 Nov 2009

Adamis Labs secures orders from three major wholesale distributers in U.S.

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that its wholly owned subsidiary, Adamis Labs has now secured distribution contracts and initial stocking orders from the three major wholesalers of prescription drugs in the U.S.

11 Nov 2009

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

OncoVista Innovative Therapies, Inc. reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen.

11 Nov 2009

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.

11 Nov 2009

Lower socioeconomic status linked with inability to fight H1N1

People who did not earn a high school diploma could be more likely to get H1N1 and the vaccine might be less effective in them compared to those who earned a diploma, new research shows.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Antibody News and Research

Further Reading

Galapagos third quarter 2009 financial results in line with management expectations

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

PDL BioPharma to pay $200 million special dividend payment to stockholders

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Innomed/BioRobotics to be Health Robotics' exclusive strategic partner in Korea

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Stapled Peptides directly inhibit the Notch transcription factor complex

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Stapled Peptides can inhibit key intracellular biological targets, says new research

NMO patients are misdiagnosed with Multiple Sclerosis, says Mayo Clinic neurologist

Adamis Labs secures orders from three major wholesale distributers in U.S.

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Lower socioeconomic status linked with inability to fight H1N1

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Immunology eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News